Testing Whether Cemiplimab (REGN2810) Plus CDX-1140 Given Prior to Surgery Are Better Than Cemiplimab (REGN2810) Alone in Patients With Stage III-IV Head and Neck Cancer
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Pfizer
Medical University of South Carolina
Yale University
National Cancer Institute (NCI)
Wake Forest University Health Sciences
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Merus B.V.
National Cancer Institute (NCI)
Boehringer Ingelheim
National Cancer Institute (NCI)
UNC Lineberger Comprehensive Cancer Center
M.D. Anderson Cancer Center
Stanford University
Medical College of Wisconsin
National Cancer Institute (NCI)
University of Edinburgh
Ensem Therapeutics
AstraZeneca
Seagen Inc.
University of Colorado, Denver
Genmab
Seagen Inc.
Seagen Inc.
Fulgent Pharma LLC.
National Cancer Institute (NCI)
AstraZeneca
Johnson & Johnson Enterprise Innovation Inc.
Merck Sharp & Dohme LLC
University of Erlangen-Nürnberg Medical School
Johnson & Johnson Enterprise Innovation Inc.
Janssen Research & Development, LLC
IRCCS Azienda Ospedaliero-Universitaria di Bologna
University of Erlangen-Nürnberg Medical School
Exelixis
Mayo Clinic
University of California, Davis
University of Erlangen-Nürnberg Medical School
University of Kentucky
Hospices Civils de Lyon
Dana-Farber Cancer Institute
National Cancer Institute (NCI)
H. Lee Moffitt Cancer Center and Research Institute
Kivu Bioscience Inc.
Vanderbilt-Ingram Cancer Center
EpiBiologics
M.D. Anderson Cancer Center
Fox Chase Cancer Center